Finance

Lists
Outlook: 50.0% bullish·16.7% bearish
Go to analysis
GMED:NYSE
Globus Medical Inc
USD 77,44
+1,53%
(+1,17) 1D
15 Okt., 09:30:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GMED...
Open
USD 77,17
High
USD 77,66
Low
USD 77,17
Mkt. cap
10,40 mjd
Avg. vol.
1,54 m
Volume
5,72 k
P/E ratio
19,80
52-wk high
USD 101,40
52-wk low
USD 58,32
EPS
USD 3,91
Beta
0,96
Shares outstanding
112,62 m
No. of employees
6 k
Open
USD 77,17
High
USD 77,66
Low
USD 77,17
Mkt. cap
10,40 mjd
Avg. vol.
1,54 m
Volume
5,72 k
P/E ratio
19,80
52-wk high
USD 101,40
52-wk low
USD 58,32
EPS
USD 3,91
Beta
0,96
Shares outstanding
112,62 m
No. of employees
6 k
News stories
From web sources and news partners
Profile
Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders. Wikipedia
About Globus Medical Inc
CEOKeith Pfeil
Employees6 k
Founded2003
Headquarters-
SectorMedical device
Analyst ratings
Based on 13 analysts giving stock ratings to GMED in the past 3 months
Buy
Buy
9
Hold
4
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for GMED in the last 3 months.
Highest
Current USD 77,44
USD 117,00 (+51,08%)
Average
USD 98,75 (+27,52%)
Lowest
USD 82,00 (+5,89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Stephan
Stifel Nicolaus
Hold
Reiterated
USD 85,00
+9,8%
10/07/2026
Kendall Au
RBC Capital
Buy
Maintained
USD 85,00
+9,8%
10/01/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
USD 85,00
+9,8%
10/01/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
09/18/2026
Vik Chopra
BMO Capital
Buy
Maintained
USD 94,00
+21,4%
08/27/2026
Caitlin Roberts
Canaccord Genuity
Buy
Reiterated
USD 115,00
+48,5%
08/28/2026
Keith Hinton
Freedom Capital Markets
Hold
Maintained
USD 87,00
+12,3%
08/27/2026
Travis Steed
Bank of America Securities
Buy
Maintained
USD 106,00
+36,9%
08/19/2026
Richard Newitter
Truist Financial
Buy
Reiterated
USD 100,00
+29,1%
08/07/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
USD 100,00
+29,1%
08/07/2026
David Saxon
Needham
Buy
Reiterated
USD 117,00
+51,1%
08/07/2026
Rishi Jaluria
RBC Capital
Buy
Maintained
USD 115,00
+48,5%
08/06/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
USD 99,00
+27,8%
08/07/2026
Mathew Blackman
TD Cowen
Buy
Maintained
USD 115,00
+48,5%
08/06/2026
Unknown Analyst
UBS
Hold
Initiated
USD 82,00
+5,9%
07/28/2026
Patrick Wood
UBS
Hold
Initiated
USD 82,00
+5,9%
07/28/2026
Unknown Analyst
BMO Capital
Buy
Initiated
USD 94,00
+21,4%
07/09/2026
Matt Miksic
Barclays
Buy
Maintained
USD 123,00
+58,8%
05/11/2026
Caitlin Cronin
Canaccord Genuity
Buy
Reiterated
USD 115,00
+48,5%
05/08/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
USD 1,34 / USD 1,10
+21,91%beat
Revenue / Est. (USD)
789,61 m / 782,98 m
+0,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
769,05 m
826,42 m
759,85 m
789,61 m
Cost of goods sold
246,13 m
254,62 m
234,07 m
241,44 m
Cost of revenue
246,13 m
254,62 m
234,07 m
241,44 m
Research and development expenses
38,07 m
36,16 m
36,51 m
36,32 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
284,19 m
304,78 m
297,77 m
286,82 m
Operating expense
352,10 m
370,30 m
363,81 m
352,70 m
Total operating expenses
598,23 m
624,93 m
597,87 m
594,14 m
Operating income
170,82 m
201,49 m
161,98 m
195,47 m
Other non operating income
1,54 m
865,00 k
2,25 m
1,17 m
EBT including unusual items
143,99 m
169,23 m
157,07 m
189,82 m
EBT excluding unusual items
173,65 m
198,52 m
167,55 m
202,85 m
Income tax expense
25,03 m
28,64 m
32,77 m
38,25 m
Effective tax rate
17,38%
16,92%
20,86%
20,15%
Other operating expenses
-
-
-
-
Net income
118,97 m
140,59 m
124,30 m
151,57 m
Net profit margin
15,47%
17,01%
16,36%
19,20%
Earnings per share
1,18
1,28
1,12
1,34
Interest and investment income
1,46 m
3,31 m
5,43 m
7,07 m
Interest expense
-
-
-
-
Net interest expenses
1,46 m
3,31 m
5,43 m
7,07 m
Depreciation and amortization charges
-
-
-
-
EBITDA
242,02 m
270,31 m
231,93 m
265,05 m
Gain or loss from assets sale
2,31 m
4,09 m
2,45 m
3,11 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme